Following CAR-T studies earlier from Novartis, I recall that cytokine release as...

z2 7 months ago | parent | context | favorite | on: BioNTech presents positive phase 1/2 data for CAR-...

Following CAR-T studies earlier from Novartis, I recall that cytokine release as an adverse event was also highly predictive of the treatment's efficacy. So terrible as it is, it's also an indication of the immune system at work.